|Day Low/High||0.15 / 0.18|
|52 Wk Low/High||0.13 / 1.92|
The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
The Burlington, Mass.-based firm announced a proposed public offering of 4 million shares. It plans to use part of the net proceeds to fund manufacturing and commercialization of osteoarthritis knee pain treatment Zilretta.